Connect with us

Stock Market Breaking News

Premier Health (OTC:P​HGRF) (CSE:P​HGI) Signs LOI with NexTech AR Solutions to Explore Healthcare Applications of Augmented Reality Technology

Daniel Chase

Published

on

stock_price_healthcare

VANCOUVER, British Columbia, March 6, 2019 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it is working with NexTech AR Solutions (NEXCF)(CSE: NTAR) (N29.F) to explore bringing augmented reality technology to its patient-centric healthcare app.

Premier Health will be working with NexTech to develop education tools for healthcare professionals and patients alike – some of which will be created and commercialized content for third parties. Utilizing AR as a learning tool in training healthcare professionals creates a highly engaging and immersive educational experience which aids in retention and how well complex concepts can be grasped. For patients, AR can potentially empower them to play a more proactive role in their own care through aiding in self-diagnosis. And finally, for third party content, the companies will explore topics such as education on medications for Pharma and Continuous Positive Airway Pressure (CPAP) therapy systems for Sleep Apnea Clinics.

In addition, the companies will investigate possible AR treatment delivery options. For example, in relation to physiotherapy, digital demonstrations can be mapped directly onto the movements patients perform as part of their recovery.

“At Premier Health we pride ourselves in being at the forefront of changes in healthcare, so we are thrilled to be a part of the future of healthcare by enabling state of the art technological advancements to our patient centric telemedicine app,” said Dr. Essam Hamza, CEO of Premier Health. “AR has the potential to revolutionize both the access to data and the delivery of healthcare. The technology will help doctors and patients alike – doctors will have access to the latest and most relevant information about their patients while patients can use AR for self-education and improving the quality of treatment they receive.”

“We are excited to work with the team at Premier Health to explore creating a custom AR and AI solution to address the healthcare market which represents another multi-billion dollar vertical ripe for disruption,” comments Evan Gappelberg CEO of NexTech. “AR allows medical knowledge, skills and expertise to be shared remotely in the moment, ensuring they get where they are needed most”.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dr. Essam Hamza, MD”
Chief Executive Officer

About Premier Health
Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global healthcare industry. We are developing innovative healthcare approaches that combine human skill-based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue, is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The Premier Health team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.

About NexTech
NexTech is bringing a next-generation web enabled augmented reality (AR) platform with Artificial Intelligence (AI) and analytics using an xAPI to the Cannabis industry, eCommerce, education, training, healthcare and video conferencing. Having integrated with Shopify, Magento and WordPress its technology offers eCommerce a universal 3D shopping solution. With just a few lines of embedded code, the company’s web-enabled patent-pending platform offers the most technologically advanced 3D-AR technology anywhere.  Online retailers can subscribe to NexTech’s state of the art, 3D-AR/AI solution for $79/mo. The company has created the AR industries first end-to-end affordable, intelligent, frictionless, scalable platform.

Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc. Midam was hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 CASH for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). Midam has been compensated an additional $100,000 by Premier Health Group to extend the period of coverage to May 1, 2019. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

Continue Reading
Click to comment

Featured

ParcelPal (PTNYF) (PKG) Continues National Expansion Strategy by Launching in Toronto, Ontario

Joe Samuel

Published

on

delivery stocks to buy

VANCOUVER, British Columbia, July 18, 2019 /PRNewswire/ — ParcelPal Technology Inc. (“ParcelPal”), (PKG.CN) (PT0.F) (PTNYF) is pleased to announce that it plans to continue its national rollout to Ontario, aiming at Canada’sfinancial capital, Toronto, as its initial launching point.

ParcelPal has secured an office in Toronto, and is currently onboarding all key personnel to fill all necessary roles for the upcoming launch, which is expected to occur shortly. ParcelPal is also actively looking to expand with new and existing partnerships within this region.

[FREE REPORT] Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market

ParcelPal’s mission is to exponentially grow its business by making mobile on-demand deliveries a common, widespread service throughout cities across Canada. The Company has been operating successfully in Vancouver, Calgary and Saskatoon and is now focusing its expansion plans in Ontario as part of its on-going strategy for Canada wide distribution. As the largest market in Canada, the Province of Ontario has over 14 million residents and represents a significant increase in the size of the markets currently being serviced by ParcelPal.

Following the announced partnership with Cowbell Brewing Co. (“Cowbell”) last month, ParcelPal plans to start servicing clients in Ontario starting with the Greater Toronto Area (“GTA”) and later rolling out to other cities within Ontario.

ParcelPal will be launching with all verticals offered (Food, alcohol, grocery, and ‘Get Anything’). ParcelPal is also in late stage planning for implementation of cannabis delivery in the province of Ontario. ParcelPal will make entry to strategic urban cities in the Province during its first and second phase of its rollout plan. This in turn will allow ParcelPal to continue its rapid growth whilst ensuring a superior customer experience as witnessed in other cities that are currently being serviced by ParcelPal.

President and CEO, Kelly Abbott states, “We are very pleased to be able to offer ParcelPal services to the residents of Toronto. Ontario is Canada’s largest province, and we are excited by the opportunity that it presents to us and our shareholders. We feel an expansion to Ontario will bring great value to our various stakeholders and with the up coming launch will be the cornerstone for all expansions moving forward. Our increased investments in technology, brand and delivery are on track to make our service even easier to use, whilst expanding our customer’s choices. I’m pleased with the strong results of the past year and excited by our opportunity for accelerated growth across Canada.”

Director and Chief strategy officer Peter Hinam states, “We have worked long and hard to achieve this important milestone in our company’s growth. We feel it will bring ParcelPal to the next level by offering our unequal service in Canada’s most populated city.”

About ParcelPal Technology Inc.

ParcelPal is a technology-driven logistics company that connects consumers to the goods they love. Customers can shop at partner businesses and through the ParcelPal technology receive their purchased goods within an hour. ParcelPal offers on-demand delivery of merchandise from leading retailers, restaurants, medical marijuana dispensaries and liquor stores in Vancouver and soon in major cities Canada-wide.

ParcelPal Website: www. parcelpal. com

The Canadian Securities Exchange (“CSE”) or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release that has been prepared by management.

CSE – Symbol: PKG
FSE – Symbol: PT0
OTC – Symbol: PTNYF

Forward Looking Information

We seek safe harbour

This news release contains forward looking statements relating to the Proposed Transaction, and the future potential of ParcelPal. Forward looking statements are often identified by terms such as “will”, “may”, “should”, “intends”, “anticipates”, “expects”, “plans” and similar expressions. All statements other than statements of historical fact, included in this release are forward looking statements that involve risks and uncertainties. These risks and uncertainties include, without limitation, the risk that the Proposed Transaction will not be completed due to, among other things, failure to execute definitive documentation, failure to complete satisfactory due diligence, failure to receive the approval of the CSE and the risk that ParcelPal will not be successful due to, among other things, general risks relating to the mobile application industry, failure of ParcelPal to gain market acceptance and potential challenges to the intellectual property utilized in ParcelPal. There can be no assurance that any forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. 

ParcelPal cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and ParcelPal will only update or revise publicly any of the included forward looking statements as expressly required by Canadian securities laws.

Contact: 
Peter Hinam, 
Director-Investor Relations 
peter@ parcelpal . com 
604-401-8700

Continue Reading

Biotechnology

PharmaCyte Biotech (PMCB) Appoints Cellular Expert to Medical and Scientific Advisory Board

Joe Samuel

Published

on

biotech penny stocks to buy

LAGUNA HILLS, Calif.–(BUSINESS WIRE)–PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed David A. Judd to PharmaCyte’s Medical and Scientific Advisory Board. Mr. Judd has had over 30 years of experience in the research and development of cell culture materials and methods for the culturing various types of human cells. Most importantly, Mr. Judd has worked for many years with the cells that PharmaCyte uses in its treatment of cancer and has a wealth of knowledge regarding their growth properties.


[Free Report] The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company


PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We feel the appointment of Mr. Judd to our Medical and Scientific Advisory Board comes at a crucial time as we work with our colleagues at Austrianova to conduct the final manufacturing runs to produce successfully the encapsulated cells that are needed for our clinical trial in locally advanced, non-metastatic, pancreatic cancer.”

Mr. Waggoner continued, “Mr. Judd was so intrigued by the possibility that our platform technology may change the way many solid tumors are treated, with little to no chemotherapy side effects, that he volunteered to work with us months ago. He has made significant contributions to our efforts in working with Austrianova to ensure that the cells from our Master Cell Bank grow as they should, both pre and post-encapsulation. During a critical time in realigning certain aspects of the manufacturing process, Mr. Judd accompanied us as an advisor to Austrianova’s cGMP manufacturing facility in Bangkok, Thailand, where the encapsulation of our cells is taking place.

“In a recent video interview, which can be viewed at www.PharmaCyte.com/Media, I spoke to why we selected Mr. Judd to join our team and the contributions he has already made to our Cancer Program. We believe that Mr. Judd’s talents and expertise will be invaluable in the development of cellular therapies for cancer as well as our efforts in the development of cellular therapies for diabetes.”

Mr. Judd is a graduate of the Biotechnology program at Rochester Institute of Technology, the first Biotechnology program in the United States. He has over 30 years of experience in cell culture and biochemistry in research and in a cGMP environment. Also, he has extensive experience in research and development of cell culture medium, both in the upstream and downstream processes.

Mr. Judd is currently employed by the Grand Island Biotechnology Company (Gibco) and is involved in research, process development and cGMP production of biotechnology and cell therapy processes.

Mr. Judd has been employed by Gibco (now owned by ThermoFischer Scientific) for 29 years and is a co-inventor on 5 patents involving cell culture materials.

About PharmaCyte Biotech:

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

Continue Reading

Featured

Stock Price Monday Morning Update – July 15, 2019

A. Lawrence

Published

on

stock price today

List Of Biotech Stocks To Watch This Quarter

Biotech has been one of the hottest sectors for the past few years. Much of that is due to the fact that there are many biotech stocks doing highly innovative work.

Click To Read More


3 Tech Stocks To Watch For July

For the past few decades, tech stocks have almost always been the most popular stocks in the market. Considering the sort of returns some of the tech giants have generated over decades, it doesn’t come as a surprise.

Click For More


Gold Prices Have Investors Scrambling & Analysts Clamoring For Junior Gold Stocks

Gold has long been a safe haven stock. But as the market turned toward tech, precious metal stocks took a back seat…until now. Could the timing of gold’s next bull run be perfect right now?

Continue Reading

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com